Contents

**Preface XI**



Preface

• Minority patients

• Clinical trials.

• Medically compromised patients and

tional scientific and professional journals.

• Women

population.

The book Clinical Trials in Vulnerable Populations has 12 chapters divided in four sections:

More than 30 authors came from different countries of the world, from Serbia to Turkey. The editor of this book is Professor Milica Prostran MD, Ph.D. Professor Prostran is a phar‐ macologist as well as a clinical pharmacologist with a subspecialty in clinical pharmacology - pharmacotherapy. This editorial task was due to her vast experience with publishing in respected international journals. She has published more than 200 *in extenso* papers in inter‐ national journals indexed in CC/SCI, and over 50 chapters in international and national books. Professor Prostran serves as a member (and referee) of the Editorial Board of several highly respected international journals - *Frontiers in Ageing Neuroscience*, where she is an As‐ sociate Editor, *Frontiers in Pharmacology*, *Current Medicinal Chemistry*, as well as several na‐

"Vulnerable subject - a subject who is at risk (from trialist rather than from disease). Exam‐ ples include patients with very serious diseases and with high expectations of the benefits of a new product, subjects who have a working relationship with investigators (medical stu‐

Some authors make a distinction between a vulnerable population and a special research

A vulnerable population includes children and minors, pregnant women, fetuses and human *in vitro* fertilization. Also, cognitive impaired persons and prisoners are included in this group. On the other hand, a special population includes students, residents, employees, terminally

The potential reader is shown the modern approach to clinical trials in vulnerable popula‐ tions, from different points of view (Medič et al., 2016). The chapters deal at length and clari‐ ty with their topics. Finally, I believe that this book I edited and reviewed with dedication will capture the attention of many readers, from medical students to practicing doctors and pharmacists. All of them must consider this very important field of medicine: clinical trial in vulnerable patients. Also, I believe that the answers to their questions may be found in this

dents, nurses, employees of pharmaceutical companies, etc." (Day, 2007).

ill patients and minorities (Prostran et al., 2012, Prostran et al., 2016).

book and may make their practice at least more bearable.

